Lexicon Pharmaceuticals, Inc.
- Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure - January 14, 2021
- FDA Issues Complete Response Letter for Zynquista (sotagliflozin) - March 25, 2019
- FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes - January 17, 2019
- FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes - May 22, 2018
- Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes - March 26, 2018
Drugs Associated with Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.